IFITM1 Antikörper (C-Term)

Produktnummer ABIN1680390

Produktdetails anti-IFITM1 Antikörper

Target: IFITM1 (Interferon-Induced Transmembrane Protein 1 (IFITM1))

Bindungsspezifität: C-Term

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser IFITM1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC)

Sequenz: CCLGFIAFAY SVKSRDRKMV GDVTGAQAYA STAKCLNIWA LILGILMTIG FILLLVFGSV TVYHIMLQII QEKRGY

Kreuzreaktivität: Human, Maus

Produktmerkmale: Polyclonal Antibodies

Aufreinigung: Affinity purification

Immunogen: A synthetic peptide corresponding to a sequence within amino acids 50 to the C-terminus of human IFITM1 (NP_003632.3).

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB,1:200 - 1:2000,IHC,1:50 - 1:200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Avoid freeze / thaw cycles.

Referenzen für anti-IFITM1 Antikörper (ABIN1680390)

Teng, Luo, Yu, Chen, Huang, Chen, Xie, Zeng, Luo, Xiong, Liu, Hou, Feng: "CRISPR/Cas9-mediated deletion of miR-146a enhances antiviral response in HIV-1 infected cells." in: Genes and immunity, (2018) (PubMed).

Details zu IFITM1

Target: IFITM1 (Interferon-Induced Transmembrane Protein 1 (IFITM1))

Andere Bezeichnung: IFITM1 (IFITM1 Produkte)

Synonyme: 9-27 antikoerper, CD225 antikoerper, DSPA2a antikoerper, IFI17 antikoerper, LEU13 antikoerper, 1110036C17Rik antikoerper, Mil-2 antikoerper, Mil2 antikoerper, interferon induced transmembrane protein 1 antikoerper, interferon induced transmembrane protein 1 (9-27) antikoerper, Ifitm1 antikoerper, IFITM1 antikoerper

Hintergrund: IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2, Marburg virus (MARV, Ebola virus (EBOV, Dengue virus (DNV, West Nile virus (WNV, human immunodeficiency virus type 1 (HIV-1 and hepatitis C virus (HCV. Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry and SARS-CoV and SARS-CoV-2 S protein-mediated viral entry. Also implicated in cell adhesion and control of cell growth and migration. Inhibits SARS-CoV-2 S protein-mediated syncytia formation. Plays a key role in the antiproliferative action of IFN-gamma either by inhibiting the ERK activation or by arresting cell growth in G1 phase in a p53-dependent manner. Acts as a positive regulator of osteoblast differentiation. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation. IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome.,IFITM1,9-27,CD225,DSPA2a,IFI17,LEU13,Cancer,Tumor biomarkers,Tumor suppressors,p53 pathway,Signal Transduction,Immunology & Inflammation,CD markers,Cytokines,Interferons,Cell Intrinsic Innate Immunity Signaling Pathway,Stem Cells,IFITM1

Molekulargewicht: 13 kDa

Gen-ID: 8519

UniProt: P13164